FIELD: biotechnology.
SUBSTANCE: invention relates to use of a conjugate of diphtheria toxin and human interleukin-3 (DT-IL3) together with a. Jak inhibitor selected from ruxolitinib and pacritinib, or b. hypomethylating agent selected from azacitidine and decitabine, for treating and inhibiting myeloproliferative neoplasm.
EFFECT: present invention provides treating myeloproliferative neoplasm.
17 cl, 4 dwg, 2 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNOTHERAPY USING ANTIBODIES BINDING PROGRAMMED CELL DEATH PROTEIN LIGAND 1 (PD-L1) | 2017 |
|
RU2766582C2 |
| DIAGNOSTIC AND THERAPEUTIC METHODS ASSOCIATED WITH TH2 INHIBITION | 2020 |
|
RU2832013C2 |
| THERAPEUTIC COMBINATIONS CONTAINING ANTI-CD123 IMMUNOCONJUGATES | 2020 |
|
RU2832141C2 |
| FGFR2 INHIBITORS SEPARATELY OR IN COMBINATION WITH IMMUNOSTIMULATING AGENTS IN CANCER TREATMENT | 2016 |
|
RU2745707C2 |
| IMMUNOTHERAPY USING ANTIBODIES BINDING PROTEIN 1 OF PROGRAMMED CELL DEATH (PD-1) | 2017 |
|
RU2768404C2 |
| FGFR2 INHIBITORS ALONE OR IN COMBINATION WITH IMMUNOSTIMULATING AGENTS IN TREATING CANCER | 2016 |
|
RU2834309C2 |
| METHODS OF TREATING TISSUE CALCIFICATION | 2015 |
|
RU2770698C2 |
| AGONISTS AND ANTAGONISTS OF HYBRID IL-1 RECEPTOR OF I TYPE | 2011 |
|
RU2754957C2 |
| COMPOSITIONS AND METHODS FOR INCREASING OR ENHANCING TRANSDUCTION OF GENE THERAPY VECTORS AND FOR REMOVING OR REDUCING IMMUNOGLOBULINS | 2021 |
|
RU2841237C1 |
| ANTI-LAG-3 DOSING REGIMENS AND THEIR USE | 2018 |
|
RU2801208C2 |
